{"id":44524,"date":"2022-05-31T19:02:08","date_gmt":"2022-05-31T17:02:08","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/global-proleukin-market-report-to-2027-players-include-chiron-and-prometheus-laboratories-researchandmarkets-com\/"},"modified":"2022-05-31T19:02:08","modified_gmt":"2022-05-31T17:02:08","slug":"global-proleukin-market-report-to-2027-players-include-chiron-and-prometheus-laboratories-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/global-proleukin-market-report-to-2027-players-include-chiron-and-prometheus-laboratories-researchandmarkets-com\/","title":{"rendered":"Global Proleukin Market Report to 2027 – Players Include Chiron and Prometheus Laboratories – ResearchAndMarkets.com"},"content":{"rendered":"
\n

DUBLIN–(BUSINESS WIRE)–The “Proleukin Market 2021-2027”<\/a> report has been added to ResearchAndMarkets.com’s<\/strong> offering.\n<\/p>\n

<\/a><\/p>\n

\nThe global proleukin market is anticipated to grow at a considerable CAGR during the forecast period. The rising prevalence of cancer among geriatric population is the major factor that has increased the demand for proleukin drug in cancer treatment.\n<\/p>\n

\nAccording to the American Institute of Cancer Research, kidney cancer is the ninth most frequent cancer among males and the fourteenth most common cancer among females. In 2018, there were approximately 400,000 new cases of kidney cancer. Proleukin is used to treat benign and malignant tumours in individuals with kidney cancer.\n<\/p>\n

\nThus, with increased cancer prevalence, the market for proleukin drug is expected to increase. The strategic initiatives such as new product launch, mergers and acquisition, business expansion is also the factor that has spurred the market growth. For instance, in February 2019, Clinigen Group plc the global pharmaceutical and services company, has signed an agreement with Novartis to acquire the US rights to Proleukin (aldesleukin, human recombinant interleukin-2) for up to $210m in cash.\n<\/p>\n

\nThe global proleukin market is segmented based on product and application. Based on product, the market is sub-segmented into injection, powder, and others. On the basis of application, the market is sub-segmented into hospital and pharmacy.\n<\/p>\n

\nGeographically, the global proleukin market covers the analysis of four major regions including North America (the US and Canada), Europe (UK, Germany, Italy, Spain, France, and Rest of Europe), Asia-Pacific (China, Japan, India, and Rest of Asia-Pacific), and the Rest of the World.\n<\/p>\n

\nSome of the companies operating in the global proleukin market include Chiron Corp., Prometheus Laboratories, and others.\n<\/p>\n

\nMarket Segmentation<\/strong>\n<\/p>\n